Antonella Notarnicola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonella Notarnicola has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Ingrid E. Lundberg
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet Stockholm Sweden
8 shared publications Charlotta Preger
Department of Protein Science, SciLifeLab KTH Royal Institute of Technology Stockholm Sweden
5 shared publications- Angeles Shunashy Galindo-Feria
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Center for Molecular Medicine
4 shared publications Eveline Van Gompel
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden
4 shared publicationsHelena Andersson
Department of Rheumatology Oslo University Hospital Oslo Norway
4 shared publicationsMaryam Dastmalchi
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden
4 shared publications
Latest Publications
- 11 November 2026
- Published by Wiley in Arthritis & Rheumatology
Cluster analysis identifies anti‐synthetase syndrome as a distinct and heterogeneous clinical entity: Analysis from the Classification Criteria for Anti‐Synthetase Syndrome project database
Objective: To better characterize the clinical phenotypes and heterogeneity of anti‐synthetase syndrome (ASyS), we performed unsupervised cluster analyses using clinical and serological data from the Classification Criteria for Anti‐Synthetase Syndrome (CLASS) project database. Methods: The CLASS database comprised 2,035 ASyS cases and 2,140 comparators with mimicking conditions, namely systemic autoimmune rheumatic diseases and/or interstitial lung disease (ILD), contributed by 103 centers worldwide. We applied multiple correspondence analysis followed by hierarchical clustering using 19 clinical and serological variables to classify ASyS and comparators in the entire CLASS cohort into distinct subgroups. We then repeated the cluster analysis in the ASyS cohort alone to identify phenotypic subgroups of ASyS. Results: Cluster analysis of the entire cohort identified three subgroups. Whereas Cluster 1 (n = 1,311) and Cluster 3 (n = 1,468) predominantly comprised ASyS and comparators, respectively, Cluster 2 (n = 1,105) included both groups. Interstitial pneumonia with autoimmune features (without anti‐synthetase autoantibodies) and systemic sclerosis were more prevalent in Cluster 2, whereas dermatomyositis and polymyositis were predominantly represented in Cluster 3. Cluster analysis of the ASyS cohort identified three distinct subgroups: Cluster 1 (anti‐Jo‐1‐positive, “full‐spectrum” ASyS with myositis, ILD, and arthritis; n = 1,034), Cluster 2 (ILD‐predominant; n = 581), and Cluster 3 (without ILD; n = 248). Conclusion: Cluster analyses identified ASyS as a distinct and heterogeneous clinical entity. Three distinct phenotypic clusters emerged among patients with ASyS, with ILD‐predominant cases representing the second largest subgroup, underscoring the need for classification criteria that adequately capture patients presenting with isolated ILD. image
- 11 November 2026
- Published by Wiley in Arthritis & Rheumatology
Cluster analysis identifies anti‐synthetase syndrome as a distinct and heterogeneous clinical entity: Analysis from the Classification Criteria for Anti‐Synthetase Syndrome project database
Objective: To better characterize the clinical phenotypes and heterogeneity of anti‐synthetase syndrome (ASyS), we performed unsupervised cluster analyses using clinical and serological data from the Classification Criteria for Anti‐Synthetase Syndrome (CLASS) project database. Methods: The CLASS database comprised 2,035 ASyS cases and 2,140 comparators with mimicking conditions, namely systemic autoimmune rheumatic diseases and/or interstitial lung disease (ILD), contributed by 103 centers worldwide. We applied multiple correspondence analysis followed by hierarchical clustering using 19 clinical and serological variables to classify ASyS and comparators in the entire CLASS cohort into distinct subgroups. We then repeated the cluster analysis in the ASyS cohort alone to identify phenotypic subgroups of ASyS. Results: Cluster analysis of the entire cohort identified three subgroups. Whereas Cluster 1 (n = 1,311) and Cluster 3 (n = 1,468) predominantly comprised ASyS and comparators, respectively, Cluster 2 (n = 1,105) included both groups. Interstitial pneumonia with autoimmune features (without anti‐synthetase autoantibodies) and systemic sclerosis were more prevalent in Cluster 2, whereas dermatomyositis and polymyositis were predominantly represented in Cluster 3. Cluster analysis of the ASyS cohort identified three distinct subgroups: Cluster 1 (anti‐Jo‐1‐positive, “full‐spectrum” ASyS with myositis, ILD, and arthritis; n = 1,034), Cluster 2 (ILD‐predominant; n = 581), and Cluster 3 (without ILD; n = 248). Conclusion: Cluster analyses identified ASyS as a distinct and heterogeneous clinical entity. Three distinct phenotypic clusters emerged among patients with ASyS, with ILD‐predominant cases representing the second largest subgroup, underscoring the need for classification criteria that adequately capture patients presenting with isolated ILD. image
- Open Access
- 5 October 2026
- Published by Elsevier in SSRN Electronic Journal
Association of longitudinal anti-Jo1 autoantibody levels with clinical phenotype and disease activity in anti-synthetase syndrome
Anti-Jo1 autoantibodies (aJo1), targeting histidyl-tRNA synthetase (HisRS), are the most common diagnostic biomarker of anti-synthetase syndrome (ASyS), although their value for disease monitoring remains unclear. We investigated longitudinal aJo1 levels and their associations with disease activity, clinical phenotype, and prognosis in 50 patients with aJo1-positive ASyS. Serum samples (n = 159), collected near diagnosis (baseline) and during follow-up at Karolinska University Hospital were analyzed using an in-house electrochemiluminescence immunoassay to measure aJo1 and HisRS levels. Prospectively collected clinical and disease activity data were evaluated at each sampling time and last follow-up; remission/low disease activity was defined as physician global assessment (PhGA) ≤20 and/or physician judgment. Longitudinal aJo1 levels showed individual variability and generally paralleled physician/patient global assessments and extra-muscular disease activity. HisRS levels were inversely correlated with aJo1 levels (rho = -0.50, p < 0.001). Higher baseline aJo1 levels were associated with development of interstitial lung disease (ILD) (p < 0.05), and a discriminative baseline cut-off for ILD was identified. aJo1 levels declined significantly between the first and second samples (median reduction 71%; p < 0.001). Patients achieving remission/low disease activity at the second sampling exhibited a greater reduction in aJo1 levels than those with moderate/high disease activity (82% vs 0%, p = 0.007). Higher baseline aJo1 levels were also associated with better outcomes at the last evaluation. These findings suggest that longitudinal aJo1 levels reflect changes in disease activity and that baseline aJo1 levels may have prognostic value, supporting their potential use as biomarkers for disease monitoring in ASyS.
- 5 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAssociation of longitudinal anti-Jo1 autoantibody levels with clinical phenotype and disease activity in anti-synthetase syndrome
Anti-Jo1 autoantibodies (aJo1), targeting histidyl-tRNA synthetase (HisRS), are the most common diagnostic biomarker of anti-synthetase syndrome (ASyS), although their value for disease monitoring remains unclear. We investigated longitudinal aJo1 levels and their associations with disease activity, clinical phenotype, and prognosis in 50 patients with aJo1-positive ASyS. Serum samples (n = 159), collected near diagnosis (baseline) and during follow-up at Karolinska University Hospital were analyzed using an in-house electrochemiluminescence immunoassay to measure aJo1 and HisRS levels. Prospectively collected clinical and disease activity data were evaluated at each sampling time and last follow-up; remission/low disease activity was defined as physician global assessment (PhGA) ≤20 and/or physician judgment. Longitudinal aJo1 levels showed individual variability and generally paralleled physician/patient global assessments and extra-muscular disease activity. HisRS levels were inversely correlated with aJo1 levels (rho = -0.50, p < 0.001). Higher baseline aJo1 levels were associated with development of interstitial lung disease (ILD) (p < 0.05), and a discriminative baseline cut-off for ILD was identified. aJo1 levels declined significantly between the first and second samples (median reduction 71%; p < 0.001). Patients achieving remission/low disease activity at the second sampling exhibited a greater reduction in aJo1 levels than those with moderate/high disease activity (82% vs 0%, p = 0.007). Higher baseline aJo1 levels were also associated with better outcomes at the last evaluation. These findings suggest that longitudinal aJo1 levels reflect changes in disease activity and that baseline aJo1 levels may have prognostic value, supporting their potential use as biomarkers for disease monitoring in ASyS.
- Open Access
- 27 August 2026
- Published by Wiley in Arthritis & Rheumatology
Plasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies
Objective: Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins. Thus, we applied a dual antibody‐based proximity extension assay to profile >1000 proteins in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink Proximity Extension Assay technology. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signalling and skin associated proteins, anti‐synthetase syndrome (ASyS) for lung associated proteins, immune‐mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with anti‐MDA5 and those with anti‐Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue‐specific responses that correlate with disease activity and tissue injury in patients with IIM. image
- 27 August 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessPlasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies
Objective: Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins. Thus, we applied a dual antibody‐based proximity extension assay to profile >1000 proteins in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink Proximity Extension Assay technology. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signalling and skin associated proteins, anti‐synthetase syndrome (ASyS) for lung associated proteins, immune‐mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with anti‐MDA5 and those with anti‐Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue‐specific responses that correlate with disease activity and tissue injury in patients with IIM. image
- Top Cited PapersOpen Access
- 9 January 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 158, 103522
Sera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue
- 9 January 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 158, 103522
Top Cited PapersOpen AccessSera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue
- Open Access
- 2 December 2024
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 26 (1) , 1-4
Correction: Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome
- 2 December 2024
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 26 (1) , 1-4
Open AccessCorrection: Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome
- 18 November 2024
- Published by Elsevier in Journal of Autoimmunity
- Vol. 149, 103332
Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis
- 18 November 2024
- Published by Elsevier in Journal of Autoimmunity
- Vol. 149, 103332
Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis
- Open Access
- 25 October 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (2) , 212-225
Unraveling the Genetics of Shared Clinical and Serological Manifestations in Patients With Systemic Inflammatory Autoimmune Diseases
Objective: Systemic inflammatory autoimmune diseases (SIADs) such as systemic lupus erythematosus (SLE), primary Sjögren disease (pSS), and idiopathic inflammatory myopathies (myositis) are complex conditions characterized by shared circulating autoantibodies and clinical manifestations, including skin rashes, among others. This study was aimed at elucidating the genetics underlying these common features.Methods: We performed targeted DNA sequencing of coding and regulatory regions from approximately 1,900 immune‐related genes in a large cohort of 2,292 well‐characterized Scandinavian patients with SIADs with SLE, pSS, and myositis as well as 1,252 controls. A gene‐based functionally weighted genetic score for aggregate testing of all genetic variants, including rare variants, was complemented by in silico functional analyses and in vitro reporter experiments.Results: Case–control association analysis detected known and potentially novel genetic loci in agreement with previous genetic and transcriptomics findings linked to the SIAD autoimmune background. Intriguingly, case–case comparisons between patient subgroups with and without specific autoantibodies revealed that the subgroups defined by antinuclear antibodies and anti–double‐stranded DNA antibodies have unique genetic profiles reflecting their heterogeneity. When focusing on clinical features, we overall showed that dual‐specificity phosphatase 1 (DUSP1) protective genetic variants lead to increased gene expression and potentially to anti‐inflammatory effects on the SIAD‐associated skin phenotype. This is consistent with recent genetic findings on eczema and with the previously reported down‐regulation of the MAPK signaling‐related gene DUSP1 in other skin disorders.Conclusion: Together, this suggests common molecular mechanisms potentially underlying overlapping clinical manifestations shared among different disorders and informs clinical heterogeneity, which could be translated to improve disease diagnostic and treatment, also in more generalized disease frameworks.
- 25 October 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (2) , 212-225
Open AccessUnraveling the Genetics of Shared Clinical and Serological Manifestations in Patients With Systemic Inflammatory Autoimmune Diseases
Objective: Systemic inflammatory autoimmune diseases (SIADs) such as systemic lupus erythematosus (SLE), primary Sjögren disease (pSS), and idiopathic inflammatory myopathies (myositis) are complex conditions characterized by shared circulating autoantibodies and clinical manifestations, including skin rashes, among others. This study was aimed at elucidating the genetics underlying these common features.Methods: We performed targeted DNA sequencing of coding and regulatory regions from approximately 1,900 immune‐related genes in a large cohort of 2,292 well‐characterized Scandinavian patients with SIADs with SLE, pSS, and myositis as well as 1,252 controls. A gene‐based functionally weighted genetic score for aggregate testing of all genetic variants, including rare variants, was complemented by in silico functional analyses and in vitro reporter experiments.Results: Case–control association analysis detected known and potentially novel genetic loci in agreement with previous genetic and transcriptomics findings linked to the SIAD autoimmune background. Intriguingly, case–case comparisons between patient subgroups with and without specific autoantibodies revealed that the subgroups defined by antinuclear antibodies and anti–double‐stranded DNA antibodies have unique genetic profiles reflecting their heterogeneity. When focusing on clinical features, we overall showed that dual‐specificity phosphatase 1 (DUSP1) protective genetic variants lead to increased gene expression and potentially to anti‐inflammatory effects on the SIAD‐associated skin phenotype. This is consistent with recent genetic findings on eczema and with the previously reported down‐regulation of the MAPK signaling‐related gene DUSP1 in other skin disorders.Conclusion: Together, this suggests common molecular mechanisms potentially underlying overlapping clinical manifestations shared among different disorders and informs clinical heterogeneity, which could be translated to improve disease diagnostic and treatment, also in more generalized disease frameworks.
- Open Access
- 26 September 2023
- Published by Elsevier in EBioMedicine
- Vol. 96, 104804
Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
- 26 September 2023
- Published by Elsevier in EBioMedicine
- Vol. 96, 104804
Open AccessDistinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
- Open Access
- 12 August 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1466-1473
Autoantibodies against the melanoma differentiation–associated protein 5 in patients with dermatomyositis target the helicase domains
Clinical observations in patients with dermatomyositis (DM) and autoantibodies against the melanoma differentiation–associated protein 5 (MDA5) suggest that the autoantibodies contribute to the pathogenesis of MDA5(+) DM. To gain insight into the role of the anti-MDA5 autoantibodies, we aimed to identify their binding sites on the different domains of the MDA5 protein. We developed an in-house ELISA to assess the reactivity against the MDA5 domains (conformational epitopes) in plasma (n = 8) and serum (n = 24) samples from MDA5(+) patients with varying clinical manifestations and disease outcomes. The reactivities were also assessed using western blot (linearized epitopes). An ELISA-based depletion assay was developed to assess cross-reactivity among the different MDA5 domains. All eight plasma samples consistently showed reactivity towards conformational and linearized epitopes on the helicase domains of the MDA5 protein. The ELISA-based depletion assay suggests that anti-MDA5 autoantibodies specifically target each of the three helicase domains. Twenty-two of the 24 serum samples showed reactivity in the in-house ELISA and all 22 displayed reactivity towards the helicase domains of the MDA5 protein. Our data revealed that the main immunogenic targets of anti-MDA5 autoantibodies from MDA5(+) patients are the helicase domains. Considering that the helicase domains are responsible for the enzymatic activity and subsequent triggering of an inflammatory response, our findings suggest that binding of anti-MDA5 autoantibodies could alter the canonical activity of the MDA5 protein and potentially affect the downstream induction of a pro-inflammatory cascade.
- 12 August 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1466-1473
Open AccessAutoantibodies against the melanoma differentiation–associated protein 5 in patients with dermatomyositis target the helicase domains
Clinical observations in patients with dermatomyositis (DM) and autoantibodies against the melanoma differentiation–associated protein 5 (MDA5) suggest that the autoantibodies contribute to the pathogenesis of MDA5(+) DM. To gain insight into the role of the anti-MDA5 autoantibodies, we aimed to identify their binding sites on the different domains of the MDA5 protein. We developed an in-house ELISA to assess the reactivity against the MDA5 domains (conformational epitopes) in plasma (n = 8) and serum (n = 24) samples from MDA5(+) patients with varying clinical manifestations and disease outcomes. The reactivities were also assessed using western blot (linearized epitopes). An ELISA-based depletion assay was developed to assess cross-reactivity among the different MDA5 domains. All eight plasma samples consistently showed reactivity towards conformational and linearized epitopes on the helicase domains of the MDA5 protein. The ELISA-based depletion assay suggests that anti-MDA5 autoantibodies specifically target each of the three helicase domains. Twenty-two of the 24 serum samples showed reactivity in the in-house ELISA and all 22 displayed reactivity towards the helicase domains of the MDA5 protein. Our data revealed that the main immunogenic targets of anti-MDA5 autoantibodies from MDA5(+) patients are the helicase domains. Considering that the helicase domains are responsible for the enzymatic activity and subsequent triggering of an inflammatory response, our findings suggest that binding of anti-MDA5 autoantibodies could alter the canonical activity of the MDA5 protein and potentially affect the downstream induction of a pro-inflammatory cascade.
- Open Access
- 1 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 953-954
POS1232 EFFECT MODIFICATION OF CANCER ON THE ASSOCIATION BETWEEN DYSPHAGIA AND MORTALITY IN EARLY IDIOPATHIC INFLAMMATORY MYOPATHIES
Background The complex interactions amongst dysphagia, cancer, and mortality in idiopathic inflammatory myopathies (IIM) have never been studied. Objectives The aim of this study was to investigate the hypothesis that cancer can modify the effect of early dysphagia exposure on all-cause mortality in IIM patients. Methods A cohort of adult IIM patients with documented dysphagia exposure within 6 months of disease onset were identified from clinical registries in five countries (Sweden, Canada, Czech Republic, Denmark, and Norway). Mortality rates including 95% CI were calculated. Crude and adjusted mortality rates in IIM patients exposed to dysphagia or not were compared with Kaplan Meier curves and Cox proportional hazard models. To explore possible effect modification of cancer on the association between dysphagia and mortality, an adjusted Cox proportional hazard model stratified on cancer status and including an interaction term between dysphagia and cancer was performed. Results This study included 230 IIM adult individuals with a mean±SD age at diagnosis of 57±15 years and a mean±SD disease duration of 3±2 months. Of those, 146 (64%) were women, 122 (54%) had severe disease at baseline, 29 (13%) had cancer in the 3 years preceding IIM onset or within 6 months after IIM onset and 112 (49%) had dysphagia. When comparing the subjects unexposed or exposed to dysphagia, interstitial lung disease was less frequent (25 vs 58%), with more dermatomyositis (56 vs 28%) and less anti-synthetase syndrome (10 vs 36%) in the group exposed to dysphagia. Mortality rates per 100 person-years for IIM patients exposed to dysphagia were 2.3 (95%CI 1.0-4.5) in those without cancer compared to 33.3 (95%CI 16.6-59.2) in those with cancer. Crude survival curves for dysphagia exposure stratified by cancer status were significantly different (p Conclusion This is the first study to demonstrate effect modification of cancer on the association between dysphagia and mortality in IIM. This suggests that IIM patients with and without cancer are very different and that separate analyses for the 2 groups should be considered when the outcome of interest is mortality. Reference None. Crude and adjusted risk estimates for the association between dysphagia exposure and mortality Unadjusted survival curves Legend Differences between survival probabilities compared using the log rank test. Disclosure of Interests Valérie Leclair: None declared, Marie Holmqvist: None declared, Antonella Notarnicola: None declared, Olga Krysturfkova: None declared, Heřman Mann Speakers bureau: AbbVie, Pfizer, Novartis, UCB, Celltrion, MSD, Janssen, Eli-Lilly, Consultant of: AbbVie, Sobi, Gilead, Pfizer, Grant/research support from: Abbvie, Helena Andersson: None declared, Louise Pyndt Diederichsen: None declared, Jiří Vencovský Speakers bureau: Abbvie, Biogen, Boehringer, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Werfen, Consultant of: Abbvie, Argenx, Boehringer, Eli Lilly, Gilead, Octapharma, Pfizer, UCB, Grant/research support from: Abbvie, Ingrid E. Lundberg Shareholder of: Roche, Novartis, Consultant of: Corbus Pharmaceuticals, Inc, Astra Zeneca, Bristol Myers Squibb, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezaar, Orphazyme, Pfizer and Janssen, Grant/research support from: Astra Zeneca, Russell Steele: None declared, Marie Hudson: None declared.
- 1 June 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (Suppl 1) , 953-954
Open AccessPOS1232 EFFECT MODIFICATION OF CANCER ON THE ASSOCIATION BETWEEN DYSPHAGIA AND MORTALITY IN EARLY IDIOPATHIC INFLAMMATORY MYOPATHIES
Background The complex interactions amongst dysphagia, cancer, and mortality in idiopathic inflammatory myopathies (IIM) have never been studied. Objectives The aim of this study was to investigate the hypothesis that cancer can modify the effect of early dysphagia exposure on all-cause mortality in IIM patients. Methods A cohort of adult IIM patients with documented dysphagia exposure within 6 months of disease onset were identified from clinical registries in five countries (Sweden, Canada, Czech Republic, Denmark, and Norway). Mortality rates including 95% CI were calculated. Crude and adjusted mortality rates in IIM patients exposed to dysphagia or not were compared with Kaplan Meier curves and Cox proportional hazard models. To explore possible effect modification of cancer on the association between dysphagia and mortality, an adjusted Cox proportional hazard model stratified on cancer status and including an interaction term between dysphagia and cancer was performed. Results This study included 230 IIM adult individuals with a mean±SD age at diagnosis of 57±15 years and a mean±SD disease duration of 3±2 months. Of those, 146 (64%) were women, 122 (54%) had severe disease at baseline, 29 (13%) had cancer in the 3 years preceding IIM onset or within 6 months after IIM onset and 112 (49%) had dysphagia. When comparing the subjects unexposed or exposed to dysphagia, interstitial lung disease was less frequent (25 vs 58%), with more dermatomyositis (56 vs 28%) and less anti-synthetase syndrome (10 vs 36%) in the group exposed to dysphagia. Mortality rates per 100 person-years for IIM patients exposed to dysphagia were 2.3 (95%CI 1.0-4.5) in those without cancer compared to 33.3 (95%CI 16.6-59.2) in those with cancer. Crude survival curves for dysphagia exposure stratified by cancer status were significantly different (p Conclusion This is the first study to demonstrate effect modification of cancer on the association between dysphagia and mortality in IIM. This suggests that IIM patients with and without cancer are very different and that separate analyses for the 2 groups should be considered when the outcome of interest is mortality. Reference None. Crude and adjusted risk estimates for the association between dysphagia exposure and mortality Unadjusted survival curves Legend Differences between survival probabilities compared using the log rank test. Disclosure of Interests Valérie Leclair: None declared, Marie Holmqvist: None declared, Antonella Notarnicola: None declared, Olga Krysturfkova: None declared, Heřman Mann Speakers bureau: AbbVie, Pfizer, Novartis, UCB, Celltrion, MSD, Janssen, Eli-Lilly, Consultant of: AbbVie, Sobi, Gilead, Pfizer, Grant/research support from: Abbvie, Helena Andersson: None declared, Louise Pyndt Diederichsen: None declared, Jiří Vencovský Speakers bureau: Abbvie, Biogen, Boehringer, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Werfen, Consultant of: Abbvie, Argenx, Boehringer, Eli Lilly, Gilead, Octapharma, Pfizer, UCB, Grant/research support from: Abbvie, Ingrid E. Lundberg Shareholder of: Roche, Novartis, Consultant of: Corbus Pharmaceuticals, Inc, Astra Zeneca, Bristol Myers Squibb, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezaar, Orphazyme, Pfizer and Janssen, Grant/research support from: Astra Zeneca, Russell Steele: None declared, Marie Hudson: None declared.